Skip to main content
SpringerLink
Log in
Book cover

Proton Pump Inhibitors pp 91–115Cite as

Birkhäuser

Consequences of gastric acid inhibition in man

  • Chapter

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

For more than 100 years it has been known that gastric acid secretion is not the only but an essential causative factor in the pathogenesis of acid-related diseases. Thus reduction of acid secretion became a major therapeutic goal. For most of this century, effective acid reduction could be achieved only by surgery (gastric resection and vagotomy). The introduction of potent inhibitors of acid secretion, that is the H2-receptor blocking agent cimetidine and its analogues in the late seventies and the even more potent proton pump inhibitor (PPI) omeprazole and its analogues in the late eighties have revolutionized therapy. Surgery became superfluous for benign oesophagogastric diseases, except in case of perforation or haemorrhage. However, soon after the introduction of the H2-receptor blockers concern was expressed about the risk of hypochlorhydria or achlorhydria. This concern originates in the conviction that gastric acid is needed for normal life and that achlorhydria will cause serious problems. But do we really know how much gastric acid we need?

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Frontiers in digestive diseases: omeprazole. Dig Dis Sci (1995); 40(Suppl): 1S–131S

    Google Scholar 

  2. Creutzfeldt W (1988) The achlorhydria-carcinoid sequence: role of gastrin. Digestion 39: 61–79

    PubMed  CAS  Google Scholar 

  3. Creutzfeldt W, Lamberts R (1991) Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 26 (Suppl 180): 179–191

    Google Scholar 

  4. Creutzfeldt W (1994) Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Ding Safety 10: 66–82

    CAS  Google Scholar 

  5. Yeomans ND (ed) (1993) Inhibition of gastric acid secretion. Baillière’s Clinical Gastroenterology 1: 1–194

    Google Scholar 

  6. Modlin IM, Goldenring JR, Lawton GP, Hunt R (1994) Aspects of the theoretical basis and clinical relevance of low acid states. Am J Gastroenterol 89: 308–318

    PubMed  CAS  Google Scholar 

  7. Freston JW (1997) Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 92 (Suppl): 51S–57S

    PubMed  CAS  Google Scholar 

  8. Yalow RS, Berson SA (1970) Radioimmunoassay of gastrin. Gastroenterology 58: 1–14

    PubMed  CAS  Google Scholar 

  9. Lundell L, Backman L, Ekström P et al (1991) Prevention of relapse of reflux esophagitis after endoscopic healing: efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 26: 248–256

    PubMed  CAS  Google Scholar 

  10. Lanzon-Miller S, Pounder RE, Hamilton MR et al (1987) Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1: 239–251

    PubMed  CAS  Google Scholar 

  11. Lind T, Cederberg C, Olausson M, Olbe L (1990) 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 99: 1593–1598

    PubMed  CAS  Google Scholar 

  12. Brunner G, Creutzfeldt W, Harke U, Lamberts R (1989) Efficacy and safety of long-term treatment with omeprazole in patients with acid related diseases resistant to ranitidine. Can J Gastroenterol 3 (Suppl A): 72–76

    Google Scholar 

  13. Jansen JBMJ, Klinkenberg-Knol EC, Meuwissen SGM et al (1990) Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99: 621–628

    PubMed  CAS  Google Scholar 

  14. Lamberts R, Creutzfeldt W, Strüber HG et al (1993) Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 104: 1356–1370

    PubMed  CAS  Google Scholar 

  15. Brunner G, Arnold R, Hennig U, Fuchs W (1993) An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 7(Suppl 1): 51–55

    PubMed  Google Scholar 

  16. Eissele R, Brunner G, Simon B et al (1997) Gastric mucosa during treatment with lansoprazole: Helicobacterpylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 112:707–717

    PubMed  CAS  Google Scholar 

  17. Brunner G, Harke U (1994) Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 8 (Suppl 1): 59–64

    PubMed  Google Scholar 

  18. Klinkenberg-Knol EC, Jansen JBMJ, Lamers CBHW et al (1990) Temporary cessation of long-term maintance treatment with omeprazole in patients with H2-receptor-antagonistresistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. Scand J Gastroenterol 25: 1144–1150

    PubMed  CAS  Google Scholar 

  19. Wilander E (1981) Achylia and the development of gastric carcinoids. Virch Arch Abt A Path Anat 394: 151–160

    CAS  Google Scholar 

  20. Carney JA, Go VLW, Fairbanks VF, Moore SB, Alport EC, Nora FE (1983) The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 99:761–766

    PubMed  CAS  Google Scholar 

  21. Borch K, Renvall H, Liedberg G (1985) Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88: 638–648

    PubMed  CAS  Google Scholar 

  22. Borch K, Renvall H, Liedberg G, Andersen BN (1986) Relations between circulating gastrin and endocrine cell proliferation in the atrophie gastric fundic mucosa. Scand J Gastroenterol 21: 357–363

    PubMed  CAS  Google Scholar 

  23. Solcia E, Bordi C, Creutzfeldt W et al (1988) Histopathological classification of nonantral gastric endocrine growth in man. Digestion 41: 185–200

    PubMed  CAS  Google Scholar 

  24. Solcia E, Capella C, Fiocca R et al (1990) Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 14: 503–513

    PubMed  CAS  Google Scholar 

  25. Maton PN, Lack EE, Collen MJ et al (1990) The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 99: 943–950

    PubMed  CAS  Google Scholar 

  26. Solcia E, Rindi G, Havu N, Elm G (1989) Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol 24(Suppl 166): 129–137

    Google Scholar 

  27. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ et al (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121: 161–167

    PubMed  CAS  Google Scholar 

  28. Koop H, Frank M, Kuly S et al (1993) Gastric argyrophil (enterochromaffin-like), gastrin, and somatostatin cells after proximal selective vagotomy in man. Dig Dis Sci 38: 295–302

    PubMed  CAS  Google Scholar 

  29. Creutzfeldt W, Lamberts R (1992) Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 51 (Suppl 1): 76–81

    PubMed  Google Scholar 

  30. Solcia E, Fiocca R, Havu N et al (1992) Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 51 (Suppl 1): 82–92

    PubMed  Google Scholar 

  31. Solcia E, Fiocca R, Villani L et al (1991) Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol 26 (Suppl 180): 146–159

    Google Scholar 

  32. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al (1996) Atrophie gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole of fundoplication. N Engl J Med 334: 1018–1022

    PubMed  CAS  Google Scholar 

  33. Berstad AE, Hatlebakk JG, Maartmann-Moe H et al (1997) H. pylori gastritis and epithelial cell proliferation in patients with reflux oesophatitis after treatment with lansoprazole. Gut 41: 740–747

    PubMed  CAS  Google Scholar 

  34. Sachs G (1997) Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 112: 1033–1036

    PubMed  CAS  Google Scholar 

  35. Logan RPH, Walker MM, Misiewicz JJ et al (1995) Changes in the intragastric distribution of H. pylori during treatment with omeprazole. Gut 36: 12–16

    PubMed  CAS  Google Scholar 

  36. Lundell L, Havu N, Andersson A et al (1997) Gastritis development and acid suppression therapy revisited. Results of a randomised clinical study with long-term follow-up. Gastroenterology 112: A28

    Google Scholar 

  37. Lechago J, Correa P (1993) Prolonged achlorhydria and gastric neoplasia: is there a causal relationship? Gastroenterology 104: 1554–1557

    PubMed  CAS  Google Scholar 

  38. Rubin CE (1997) Are there three types of Helicobacter pylori gastritis? Gastroenterology 112:2108–2110

    PubMed  CAS  Google Scholar 

  39. El-Zimaity HMT, Graham DY, Al-Assi MT et al (1996) Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 27: 35–41

    PubMed  CAS  Google Scholar 

  40. Genta RM (1997) Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy. Gastroenterology 113: S51–S55

    PubMed  CAS  Google Scholar 

  41. Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. Am J Surg Pathol 20: 1161–1181

    PubMed  CAS  Google Scholar 

  42. Guillaume C, Vissuzaine C, Pospai D et al (1995) Influence des traitements prolongés par inhibiteurs de la pompe à protons sur la gastrinémie et la muqueuse fundique. Gastroenterol Clin Biol 19: 811–817

    Google Scholar 

  43. Goh KL, Boonyapisit S, Lai KH et al (1995) Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study. J Gastroenterol Hepatol 10: 92–97

    PubMed  CAS  Google Scholar 

  44. Diebold MD, Richardson S, Duchateau A, Bigard MA, Colin R, Cortot A, Fauchere JL, Zeitoun P (1998) Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig Dis Sci 43: 1629–1635

    PubMed  CAS  Google Scholar 

  45. Howden CW, Hunt RH (1987) Relationship between gastric secretion and infection. Gut 28:96–107

    PubMed  CAS  Google Scholar 

  46. Heatley RV, Sobala GM (1993) Acid suppression and the gastric flora. Baillière’s Clin Gastroenterol 7: 167–181

    CAS  Google Scholar 

  47. Stockbruegger RW (1985) Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol (Suppl 111): 7–16

    CAS  Google Scholar 

  48. Thomas JM, Misiewicz JJ, Cook AR et al (1987) Effects of one year treatment with ranitidine and of truncal vagotomy on gastric contents. Gut 28: 726–738

    PubMed  CAS  Google Scholar 

  49. Sharma BK, Santana IA, Wood EC (1984) Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. Br Med J 280: 717–719

    Google Scholar 

  50. Saltzman JR, Kowdley KV, Pedrosa MC et al (1994) Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 106: 615–623

    PubMed  CAS  Google Scholar 

  51. Fried M, Siegrist H, Frei R et al (1994) Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35: 23–26

    PubMed  CAS  Google Scholar 

  52. Colin-Jones DG (1993) Safety of lansoprazole. Aliment Pharmacol Ther 1 (Suppl 1): 56–60

    Google Scholar 

  53. Rodriguez LAG, Ruigomez A (1997) Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 8: 571–574

    Google Scholar 

  54. Brummer RJM, Stockbrügger RW (1996) Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. Dig Dis Sci 41: 2048–2054

    PubMed  CAS  Google Scholar 

  55. Thorens J, Froehlich F, Schwizer W et al (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 39: 54–59

    PubMed  CAS  Google Scholar 

  56. Daschner F, Kappstein I, Engels I et al (1988) Stress ulcer prophylaxis and ventilation pneumonia: prevention by antibacterial cytoprotective agents? Infection Control and Hospital Epidemiol 9: 59–65

    CAS  Google Scholar 

  57. Lehot JJ, Deleat-Besson R, Bastien O et al (1990) Should we inhibit gastric acid secretion before cardiac surgery? Anesth Analg 70: 185–190

    PubMed  CAS  Google Scholar 

  58. Driks MR, Craven DE, Celli BR et al (1987) Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. N Engl J Med 317: 1376–1382

    PubMed  CAS  Google Scholar 

  59. Simms HH, DeMaria E, McDonald L et al (1992) Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma 31: 531–536

    Google Scholar 

  60. Cook D.D,, Guyatt G, Marshall J et al (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 338: 791–797

    PubMed  CAS  Google Scholar 

  61. Lewis SJ, Franco S, Young G et al (1996) Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 10: 557–561

    PubMed  CAS  Google Scholar 

  62. Koop H: Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992; 6: 399–406

    PubMed  CAS  Google Scholar 

  63. Koop H, Bachern MG (1992) Serum iron, ferritin, and Vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 14: 288–292

    PubMed  CAS  Google Scholar 

  64. Festen H, Klinkenberg-Knol E, Kuipers E et al (1993) Cobalamin absorption during omeprazole treatment: short and long-term studies. Gastroenterology 104: A77

    Google Scholar 

  65. Marcuard SP, Albemaz L, Khazanie PG (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (Vitamin B12). Ann Intern Med 120: 211–215

    PubMed  CAS  Google Scholar 

  66. Shindo K, Machida M, Fukumura M et al (1998) Omeprazole induces altered bile acid metabolism. Gut 42: 266–271

    PubMed  CAS  Google Scholar 

  67. Correa P, Haenszel W, Cuello C et al (1975) A model for gastric cancer epidemiology. Lancet 2: 58–60

    PubMed  CAS  Google Scholar 

  68. Correa P (1988) A human model of gastric carcinogenesis. Cancer Res 48: 3554–3560

    PubMed  CAS  Google Scholar 

  69. Küster G.G., Remine W, Dockerty M (1972) Gastric cancer in pernicious anaemia and in patients with and without achlorhydria. Ann Surg 175: 783–789

    PubMed  Google Scholar 

  70. Hall CN, Darkin D, Brimblecombe R, Cook AJ, Kirkham JS, Northfield TC (1986) Evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut 27: 491–498

    PubMed  CAS  Google Scholar 

  71. Hall CN, Kirkham JS, Northfield TC (1987) Urinary N-nitrosoproline excretion: a further evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut 28: 216–220

    PubMed  CAS  Google Scholar 

  72. Houghton PWJ, Leach S, Owen RW et al (1989) Use of a modified N-nitrosoproline test to show intragastric nitrosation in patients at risk of gastric cancer. Br J Cancer 60: 231–234

    PubMed  CAS  Google Scholar 

  73. Sobala GM, Pignatelli B, Schorah CJ et al (1991) Levels of nitrite, nitrate, n-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis 2: 193–198

    Google Scholar 

  74. Yeomans ND, Brimblecombe RW, Elder J et al (1995) Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 40: 81S–95S

    PubMed  CAS  Google Scholar 

  75. Verdu E, Viani F, Armstrong D (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites and nitroso compounds. Gut 35: 455–460

    PubMed  CAS  Google Scholar 

  76. Milton-Thompson GJ, Lightfoot NF, Ahmet Z et al (1982) Intragastric acidity, bacteria, nitrite and N-nitroso compounds before and after cimetidine treatment. Lancet i: 1091–1095

    Google Scholar 

  77. Lechago J, Correa P (1993) Prolonged achlorhydria and gastric neoplasie: is there a causal relationship? Gastroenterology 104: 1554–1557

    PubMed  CAS  Google Scholar 

  78. Brinton LA, Gridley G, Hrubec Z et al (1989) Cancer risk following pernicious anaemia. BrJ Cancer 59: 810–813

    CAS  Google Scholar 

  79. Hsing AW, Hansson LE, McLaughlin JK et al (1993) Pernicious anemia and subsequent cancer. Cancer 71: 745–750

    PubMed  CAS  Google Scholar 

  80. Houben GMP, Stockbrügger RW (1995) Bacteria in the aetio-pathogenesis of gastric cancer: a review. Scand J Gastroenterol 30(Suppl 212): 13–18

    Google Scholar 

  81. Fuchs CS, Mayer RJ (1995) Gastric carcinoma. N Engl J Med 333: 32–41

    PubMed  CAS  Google Scholar 

  82. Lundegardh G, Adami HO, Helmick C et al (1988) Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 319: 195–200

    PubMed  CAS  Google Scholar 

  83. Tersmette AC, Offerhaus GJA, Termette KWF et al (1990) Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 50: 6486–6489

    PubMed  CAS  Google Scholar 

  84. Kokkola A, Sjöblom SM, Haapiainen R, Sipponen P et al (1998) The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. Scand J Gastroenterol 33: 88–92

    PubMed  CAS  Google Scholar 

  85. Godwin DJ (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36: 560–569

    PubMed  Google Scholar 

  86. Rindi G, Luinerti O, Cornaggia M, Capeila C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104: 994–1006

    PubMed  CAS  Google Scholar 

  87. Rappel S, Altendorf-Hofmann A, Stolte M (1995) Prognosis of gastric carcinoid tumours. Digestion 56: 455–462

    PubMed  CAS  Google Scholar 

  88. Waldum HL, Haugen OA, Isaksen C et al (1991) Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)? Eur J Gastroenterol Hepatol 3: 245–249

    Google Scholar 

  89. Creutzfeldt W, Solcia E (1991) Are diffuse gastric carcinomas neuroendocrine tumours ECL-omas? Eur J Gastroenterol Hepatol 3:179–191

    Google Scholar 

  90. Weinstock J, Baldwin GS (1988) Binding of gastrin-17 to human gastric carcinoma cell lines. Cancer Res 48: 932–937

    PubMed  CAS  Google Scholar 

  91. Watson S, Durrant L, Morris D (1989) Gastrin: growth enhancing effect on human gastric and colonie tumor cells. Br J Cancer 59: 554–558

    PubMed  CAS  Google Scholar 

  92. Ishizuka J, Martinez J, Townsend CM, Thompson JC (1992) The effect of gastrin on growth of human stomach cancer cells. Ann Surg 215: 528–534

    PubMed  CAS  Google Scholar 

  93. Matsushima Y, Kinoshita Y, Nakata H et al (1994) Gastrin receptor gene expression in several human carcinomas. Jpn J Cancer Res 85: 819–824

    PubMed  CAS  Google Scholar 

  94. Möller H, H,, Lindvig K, Lefter R et al (1989) Cancer occurrence in a cohort of patients treated with cimetidine. Gut 30: 1558–1562

    PubMed  Google Scholar 

  95. La Vecchia C.C,, Negri E, D’Avanzo B, Franceschi S (1990) Histamine-2-receptor antagonists and gastric cancer risk. Lancet 36: 355–357

    Google Scholar 

  96. Colin-Jones DG, Langman MJS, Lawson DH et al (1992) Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 33: 1280–1284

    PubMed  CAS  Google Scholar 

  97. Möller H, Nissen A, Mosbech J (1992) Use of cimetidine and other peptic ulcerdrugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 33: 1166–1169

    PubMed  Google Scholar 

  98. Stolte M, Bethke B, Seifert E et al (1995) Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 33: 146–149

    PubMed  CAS  Google Scholar 

  99. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al (1997) Gastric polyps during longterm omeprazole treatment for gastroesophageal reflux disease. Gastroenterology 112: A281

    Google Scholar 

  100. Sugano K, Fukushima, Yazaki Y (1997) Regression of hyperplastic polyps of the stomach by eradication of helicobacter pylori. Gastroenterology 112: A300

    Google Scholar 

  101. Beauchamp RD, Townsend CM, Singh P et al (1985) Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice. Ann Surg 202: 303–309

    PubMed  CAS  Google Scholar 

  102. Hoosein NM, Kiener PA, Curry RC et al (1988) Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res 48:7179–7183

    PubMed  CAS  Google Scholar 

  103. Hoosein NM, Kiener PA, Curry RC, Brattein MG (1990) Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide. Exp Cell Res 186: 15–21

    PubMed  CAS  Google Scholar 

  104. Graffner H, Singh G, Chaudry I, Milson JW (1992) Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma. Dig Dis Sci 37: 485–489

    PubMed  CAS  Google Scholar 

  105. Smith JP, Kramer ST, Demers LM (1993) Effects of gastrin and difluoromethylornithine on growth of human colon cancer. Dig Dis Sci 38: 520–528

    PubMed  CAS  Google Scholar 

  106. Singh P, Townsend CM, Thompson JC et al (1990) Gut hormones in colon cancer: past and prospective studies. Cancer J 3: 28–33

    CAS  Google Scholar 

  107. Smith JP, Wood JG, Solomon TE (1989) Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 34: 171–174

    PubMed  CAS  Google Scholar 

  108. Penman ID, El-Omar E, McGregor JR et al (1993) Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 34: 1559–1565

    PubMed  CAS  Google Scholar 

  109. Pinson DM, Havu N, Sztern MI et al (1995) Drug-induced hypergstrinemia: absence of trophic effects on colonie carcinoma in rats. Gastroenterology 108: 1068–1074

    PubMed  CAS  Google Scholar 

  110. Baldwin GS (1994) Anti-proliferative gastrin/cholecystokinin receptor antagonists target the 78 kDa gastrin-binding protein. Proc NatlAcad Sci USA 91: 7593–7597

    CAS  Google Scholar 

  111. Imdahl A, Mantamadiotis T, Eggstein S et al (1995) Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J Cancer Res Clin Oncol 121:661–666

    PubMed  CAS  Google Scholar 

  112. Finley GG, Koski RA, Melhem MF et al (1993) Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. Cancer Res 53: 2919–2926

    PubMed  CAS  Google Scholar 

  113. Luttichau HR, Van Solinge WW, Nielsen FC, Rehfeld JF (1993) Developmental expression of the gastrin and cholecystokinin genes in rat colon. Gastroenterology 104: 1092–1098

    PubMed  CAS  Google Scholar 

  114. Van Solinge WW, Nielsen FC, Friis-Hansen L et al (1993) Expression but incomplete maturation of progastrin in clorectal carcinomas. Gastroenterology 104: 1099–1107

    PubMed  Google Scholar 

  115. Rehfeld JF (1995) Gastrin and colorectal cancer: a never ending dispute? Gastroenterology 108: 1307–1310

    PubMed  CAS  Google Scholar 

  116. Hollande F, Imdahl A, Mantamadiotis T et al (1997) Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. Gastroenterology 113: 1576–1588

    PubMed  CAS  Google Scholar 

  117. Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A (1995) Expression, processing and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 109: 1142–1153

    PubMed  CAS  Google Scholar 

  118. Seitz JF, Giovannini M, Gouvernet J, Gauthier AP (1991) Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 13: 541–545

    PubMed  CAS  Google Scholar 

  119. Wong K, Beardshall K, Waters CM et al (1991) Postprandial hypergastrinaemia in patients with colorectal cancer. Gut 32: 1352–1354

    PubMed  CAS  Google Scholar 

  120. Penman ID, El-Omar E, Ardill JES et al (1994) Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 106: 1263–1270

    PubMed  CAS  Google Scholar 

  121. Suzuki H, Matsumoto K, Terashima H (1988) Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum 31:716–717

    PubMed  CAS  Google Scholar 

  122. Kaufmann HP, Ottenjann R (1991) Serum-Nüchtern-Gastrin-Werte bei Kolonadenomen und kolorektalen Karzinomen. Z Gastroenterol 29: 527–528

    PubMed  CAS  Google Scholar 

  123. Yapp R, Modlin IM, Kumar RR et al (1992) Gastrin and colorectal cancer evidence against an association. Dig Dis Sci 37: 481–484

    PubMed  CAS  Google Scholar 

  124. Kikendall JW, Glass AR, Sobin LH, Bowen PE (1992) Serum gastrin is not higher in subjects with colonie neoplasia. Am J Gastroenterol 87: 1394–1397

    PubMed  CAS  Google Scholar 

  125. Eisborg L, Mosbech J (1979) Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand 206: 315–318

    Google Scholar 

  126. Orbuch M, Venzon DJ, Lubensky IA et al (1996) Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci 41: 604–613

    PubMed  CAS  Google Scholar 

  127. Caygill CPJ, Hill MJ, Hall CN et al (1987) Increased risk of cancer at multiple sites after gastric surgery for peptic ulcer. Gut 28: 924–928

    PubMed  CAS  Google Scholar 

  128. Hill MJ (1983) Bile, bacteria and bowel cancer. Gut 24: 871–875

    PubMed  CAS  Google Scholar 

  129. Mullan FJ, Wilson HK, Majury CW et al (1990) Bile acids and the increased risk of colorectal tumours after truncal vagotomy. Br J Surg 77: 1085–1090

    PubMed  CAS  Google Scholar 

  130. Watt PCH, Patterson CC, Kennedy TL (1984) Late mortality after vagotomy and drainage for duodenal ulcer. BrMed J 288: 1335–1338

    CAS  Google Scholar 

  131. Bundred NJ, Whitfield BCS, Stanton E et al (1985) Gastric surgery and the risk of subsequent colorectal cancer. Br J Surg 72: 618–619

    PubMed  CAS  Google Scholar 

  132. Fisher SG, Davis F, Nelson R et al (1994) Large bowel cancer following gastric surgery for benign disease: a cohort study. Am J Epidemiol 139: 684–692

    PubMed  CAS  Google Scholar 

  133. Lundegardh G, Adami HO, Helmick C, Zack M (1990) The risk of large bowel cancer after partial gastrectomy for benign ulcer disease. Ann Surgery 212: 714–719

    CAS  Google Scholar 

  134. Möller H, H,, Toftgaard C (1991) Cancer occurrence in a cohort of patients surgically treated for peptic ulcer. Gut 32: 740–744

    PubMed  Google Scholar 

  135. Tersmette AC, Offerhaus GJA, Giardiello FM et al (1991) Long-term prognosis after partial gastrectomy for benign conditions. Gastroenterology 101: 148–153

    PubMed  CAS  Google Scholar 

  136. Macintyre IMC, O’Brien F (1994) Death from malignant disease after surgery for duodenal ulcer. Gut 35: 451–454

    PubMed  CAS  Google Scholar 

  137. Munnangi S, Sonnenberg A (1997) Colorectal cancer after gastric surgery: a metaanalysis. Am J Gastroenterol 92: 109–113

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Georg-August-University, Robert-Koch-Straße 40, D-37075, Göttingen, Germany

    Werner Creutzfeldt

Authors
  1. Werner Creutzfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Centre for Gastroenterological Research, University of Göteborg, S-41345, Göteborg, Sweden

    Lars Olbe

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Creutzfeldt, W. (1999). Consequences of gastric acid inhibition in man. In: Olbe, L. (eds) Proton Pump Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8795-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8795-3_6

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9777-8

  • Online ISBN: 978-3-0348-8795-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation